The use of probiotic L. fermentum ME-3 containing Reg'Activ Cholesterol supplement for 4 weeks has a positive influence on blood lipoprotein profiles and inflammatory cytokines: an open-label preliminary study.

What Was Tested

The paper reports a study of Copper (Supplement), published as a clinical trial.

The aim of the study was to establish if the special composition of innovative food supplement Reg'Activ Cholesterol (RAC) has a positive influence to the human body cardiovascular-inflammatory and diabetic parameters.

Why It Was Studied

Cardiovascular diseases continue to be a challenge and burden to heath.

Modifying the (common) risk factors of them is the key of longterm success.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was an open-label and pilot study.

Everyone knew when Copper (Supplement) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

The parameters measured were total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride, oxLDL, hsCRP, IL-6 and glycosylated haemoglobin (HbA1c%).

What Was Measured

PubMed files the paper under topics including Antioxidants, Cardiovascular Diseases, Cholesterol, Cholesterol, HDL, Cholesterol, LDL, Cytokines and Dietary Supplements.

Author keywords: Blood serum lipid profile, HbA1c%, Human clinical trial, L. fermentum ME-3 and Oxidized LDL.

What This Means in Plain Language

The paper is an open-label and pilot study of Copper (Supplement).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Nutrition journal), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.